Effect of empagliflozin beyond glycemic control: Cardiovascular benefit in patients with type 2 diabetes and established cardiovascular disease

This study has led to the development of ongoing trials that will establish which patients will benefit most from this therapy, particularly with regard to comorbidities.ResumoA prevalência da diabetes mellitus tipo 2 (DMT2) continua a aumentar e a sua associação com a doença cardiovascular (CV) tem levado à incorporação e valorização de endpoints CV nos ensaios clínicos sobre o tratamento da DMT2.Este artigo faz uma revisão dos vários ensaios já realizados e em desenvolvimento, neste âmbito, com especial enfoque no estudo EMPA-REG OUTCOME. Neste estudo, a empagliflozina, um inibidor do cotransportador tipo 2 de sódio-glicose (iSGLT2), demonstrou efeitos benéficos na redução do risco CV em doentes com DMT2 e doença CV estabelecida, para além de segurança CV e diminuição dos valores de HbA1c, representando uma mudança de paradigma com impacto ao nível das recomendações internacionais para o tratamento da DMT2. Estes resultados mantiveram-se em análises de subgrupos posteriores, nomeadamente na insuficiência cardíaca, doença renal crónica e doença arterial periférica, ainda que muitas questões se coloquem sobre os mecanismos envolvidos nestes efeitos - se efeitos hemodinâmicos, efeitos metabólicos ou se a diminuiçã...
Source: Revista Portuguesa de Cardiologia - Category: Cardiology Source Type: research

Related Links:

Type 2 diabetes mellitus (T2DM) is a considerable risk factor of cardiovascular disease, heart failure, chronic kidney disease, and mortality [1 –4]. Diabetes caused 4 million deaths in 2017, with more than 0.84 million in China [5]. The prevalence of T2DM is increasing in many countries with the speeding up of urbanization and change in lifestyle. The International Diabetes Federation estimated that approximately 425 million adults (20– 79 years) were living with diabetes in 2017, 79% were from low- and middle-income countries, and this number would rise to 629 million by 2045 [5].
Source: Primary Care Diabetes - Category: Primary Care Authors: Tags: Original research Source Type: research
SUMMARY Type 2 diabetes mellitus is an important public health problem, with a significant impact on cardiovascular morbidity and mortality and an important risk factor for chronic kidney disease. Various hypoglycemic therapies have proved to be beneficial to clinical outcomes, while others have failed to provide an improvement in cardiovascular and renal failure, only reducing blood glucose levels. Recently, sodium-glucose cotransporter-2 (SGLT2) inhibitors, represented by the empagliflozin, dapagliflozin, and canagliflozin, have been showing satisfactory and strong results in several clinical trials, especially regarding...
Source: Revista da Associacao Medica Brasileira - Category: General Medicine Source Type: research
Silva, FCd, Iop, RdR, Andrade, A, Costa, VP, Gutierres Filho, PJB, and Silva, Rd. Effects of physical exercise on the expression of microRNAs: A systematic review 34(1): 270–280, 2020—Studies have detected changes in the expression of miRNAs after physical exercise, which brings new insight into the molecular control of adaptation to exercise. Therefore, the objective of the current systematic review of experimental and quasiexperimental studies published in the past 10 years was to assess evidence related to acute effects, chronic effects, and both acute and chronic effects of physical exercise on miRNA expres...
Source: Journal of Strength and Conditioning Research - Category: Sports Medicine Tags: Brief Review Source Type: research
IJERPH, Vol. 17, Pages 155: Important Considerations for the Treatment of Patients with Diabetes Mellitus and Heart Failure from a Diabetologist’s Perspective: Lessons Learned from Cardiovascular Outcome Trials International Journal of Environmental Research and Public Health doi: 10.3390/ijerph17010155 Authors: Chrysi Koliaki Nicholas Katsilambros Heart failure (HF) represents an important cardiovascular complication of type 2 diabetes mellitus (T2DM) associated with substantial morbidity and mortality, and is emphasized in recent cardiovascular outcome trials (CVOTs) as a critical outcome for patients wit...
Source: International Journal of Environmental Research and Public Health - Category: Environmental Health Authors: Tags: Editorial Source Type: research
Fight Aging! publishes news and commentary relevant to the goal of ending all age-related disease, to be achieved by bringing the mechanisms of aging under the control of modern medicine. This weekly newsletter is sent to thousands of interested subscribers. To subscribe or unsubscribe from the newsletter, please visit: https://www.fightaging.org/newsletter/ Longevity Industry Consulting Services Reason, the founder of Fight Aging! and Repair Biotechnologies, offers strategic consulting services to investors, entrepreneurs, and others interested in the longevity industry and its complexities. To find out m...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
CONCLUSION: In T2DM patients, CKD presence was associated with higher risk of modified MACE, HF, and ACM. This may have risk-stratification implications for T2DM patients based on background CKD and highlights the potential importance of novel renoprotective strategies. PMID: 31812955 [PubMed - as supplied by publisher]
Source: American Journal of Nephrology - Category: Urology & Nephrology Authors: Tags: Am J Nephrol Source Type: research
The objective of this study was 1) to assess the relationship between diagnosed DLP and cardiovascular disease in COPD patients and compare it with other known cardiovascular risk factors and 2) to determine the relationship between the different cardiovascular comorbidities and the severity groups according to the GOLD 2017 classification.MethodsA cross-sectional, observational study was performed in 454 outpatients with COPD during their follow up. We calculated the prevalence of each of the cardiovascular comorbidities and the probability of each of the cardiovascular risk factors to occur jointly with a vascular diseas...
Source: Revista Clinica Espanola - Category: Internal Medicine Source Type: research
Abstract Type 2 diabetes mellitus is one of the most common form of the disease worldwide. Hyperglycemia and insulin resistance play key roles in type 2 diabetes mellitus. Renal glucose reabsorption is an essential feature in glycaemic control. Kidneys filter 160g daily of glucose in healthy subjects under euglycaemic conditions. The expanding epidemic of diabetes lead to a prevalence of diabetes-related cardiovascular disorders, in particular, heart failure and renal dysfunction. Cellular uptake glucose as a fundamental process for homeostasis, growth, and metabolism. In human, three families of glucose transport...
Source: Current Topics in Medicinal Chemistry - Category: Chemistry Authors: Tags: Curr Top Med Chem Source Type: research
Introduction: Calciphylaxis is characterized by calcification of the small and medium caliber vessels of the dermis and subcutaneous cellular tissue. It is more common in patients with chronic kidney disease (CKD) on dialysis, but is also described in patients with other risk factors such as secondary hyperparathyroidism, heart failure (HF), diabetes mellitus type 2 (DM-2), hypercoagulable states and drugs such as warfarin. The mortality rate is high, with sepsis being the most frequent complication.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research
Authors: Kartoun U, Iglay K, Shankar RR, Beam A, Radican L, Chatterjee A, Pai JK, Shaw S Abstract AIMS: To assess demographic and clinical characteristics associated with clinical inertia in a real-world cohort of type 2 diabetes mellitus patients not at hemoglobin A1c goal (
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research
More News: Cardiology | Cardiovascular | Chronic Kidney Disease | Clinical Trials | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Empagliflozin | Endocrinology | Heart | Heart Failure | Jardiance | Sodium | Study | Urology & Nephrology